Business Description
Oncternal Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US40052B2079
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 97.22 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6.4 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | 14.1 | |||||
3-Year Book Growth Rate | -39.6 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 34.59 | |||||
14-Day RSI | 40.59 | |||||
6-1 Month Momentum % | 6.4 | |||||
12-1 Month Momentum % | -0.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.66 | |||||
Quick Ratio | 4.66 | |||||
Cash Ratio | 4.42 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.5 | |||||
Shareholder Yield % | -0.35 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -96.94 | |||||
ROA % | -83.39 | |||||
ROIC % | -1655.44 | |||||
ROC (Joel Greenblatt) % | -16113.45 | |||||
ROCE % | -100.22 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.06 | |||||
Price-to-Tangible-Book | 1.06 | |||||
EV-to-EBIT | 0.07 | |||||
EV-to-EBITDA | 0.07 | |||||
EV-to-Forward-Revenue | 0.5 | |||||
EV-to-FCF | 0.09 | |||||
Price-to-Net-Current-Asset-Value | 1.09 | |||||
Price-to-Net-Cash | 1.16 | |||||
Earnings Yield (Greenblatt) % | 1428.57 | |||||
FCF Yield % | -118.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Oncternal Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -11.338 | ||
Beta | 0 | ||
Volatility % | 71.24 | ||
14-Day RSI | 40.59 | ||
14-Day ATR (€) | 0.000794 | ||
20-Day SMA (€) | 5.32 | ||
12-1 Month Momentum % | -0.75 | ||
52-Week Range (€) | 4.32 - 11.8 | ||
Shares Outstanding (Mil) | 2.96 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Oncternal Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Oncternal Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Oncternal Therapeutics Inc Frequently Asked Questions
What is Oncternal Therapeutics Inc(FRA:GTU)'s stock price today?
When is next earnings date of Oncternal Therapeutics Inc(FRA:GTU)?
Does Oncternal Therapeutics Inc(FRA:GTU) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |